I-Mab Announces Upcoming Participation at September Conferences
SHANGHAI and GAITHERSBURG, Md., Sept. 8, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in September. Details of the conferences and management presentations are as follows:
Cantor Fitzgerald Virtual Global Healthcare Conference 2020
Webcast link: https://www.webcaster4.com/Webcast/Page/2495/37179
The webcast will also be available under "Event Calendar" on IMAB's IR website at https://ir.i-mabbiopharma.com/
One-on-one meetings: September 15-17, 2020
For more information, please contact your Cantor Fitzgerald representative.
Jefferies Virtual Asia Forum
One-on-one and small group meetings: September 14-16, 2020
For more information, please contact your Jefferies representative.
ICBCI Virtual ADR New Economy Conference
One-on-one and small group meetings: September 18, 2020
For more information, please contact your ICBCI representative.
2020 Huatai USA Autumn Virtual China Conference
One-on-one and small group meetings: September 21-23, 2020
For more information, please contact your Huatai representative.
Morgan Stanley Virtual Asia Pacific Conference
One-on-one and small group meetings: September 24-25, 2020
For more information, please contact your Morgan Stanley representative.
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hong Kong and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.com
For more information, please contact:
Jielun Zhu, CFO
Gigi Feng, Vice President and Global Head of Corporate Communications
Burns McClellan, Inc. (Americas and Europe)
The Piacente Group, Inc. (Asia)
View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-september-conferences-301125446.html
Company Codes: NASDAQ-NMS:IMAB